A-shares closed · 港股休市 Quotes 行情 · 25 Sep 17:19 CST
27 Sep 2026 · 23:25 CST Terminal Access 终端入口 →
002653.SZ深圳证券交易所 · 主板 Main

Haisco Pharmaceutical Group 海思科

Chemical Pharmaceuticals 化学制药
¥61.31−¥4.15 · −6.34%Delayed 行情延迟 · 24 Sep 2026 · 16:14 CST · CNY
Open 开盘
¥65.00
High 最高
¥65.38
Low 最低
¥61.08
Prev Close 昨收
¥65.46
Volume 成交量
595.1万股
Turnover 成交额
¥3.69亿
Mkt Cap 总市值
¥699亿
P/E 市盈率
73.7×
Recent Activity 近期动态All Filings 全部公告 →

48 significant filings since 30 May 2026: 1 on share pledge, 22 on share issue and 10 on equity incentive, and 10 other kinds. The latest, on 18 Sep 2026: 关于2024年限制性股票激励计划第二个解除限售期解除限售条件成就的公告. On 9 Jul 2026 the company said it expects net profit for the period ending 30 Jun 2026 to rise by 513.25% to 575.35% from the same period a year earlier.
自 30 May 2026 起有 48 份重大公告:share pledge 1 份、share issue 22 份、equity incentive 10 份,另有 10 类。最新一份(18 Sep 2026):关于2024年限制性股票激励计划第二个解除限售期解除限售条件成就的公告。9 Jul 2026 公司预告截至 30 Jun 2026 的净利润较上年同期上升 513.25% 至 575.35%。

Price History 价格走势

250 trading days 个交易日 · High 最高 ¥78.58 · Low 最低 ¥42.38
45.0050.0055.0060.0065.0070.0075.00
Volume 成交量
3,074.4万
Sep 25Dec 25Mar 26Jun 26Sep 26

Against Its Own History 与自身历史比较

73.7×
Median 中值 122.7× · Range 区间 78.4× to 223.1× · 7 periods 期
14.26×
Median 中值 10.99× · Range 区间 7.03× to 15.43× · 10 periods 期

Period by Period 逐期

Period 报告期Close at Period End 期末收盘TTM EPS 滚动每股收益 BPS 每股净资产
30 Jun 2026 中报¥66.34¥0.8578.4×¥4.3015.43×
31 Mar 2026 一季报¥54.28¥0.6978.7×¥4.3312.55×
31 Dec 2025 年报¥51.32¥0.23223.1×¥3.8313.40×
30 Sep 2025 三季报¥53.46¥0.27196.0×¥3.7714.16×
30 Jun 2025 中报¥42.22¥0.34122.7×¥3.6311.63×
31 Mar 2025 一季报¥38.03¥0.31122.7×¥3.6810.35×
31 Dec 2024 年报¥33.25¥0.3595.0×¥3.768.84×
30 Sep 2024 三季报¥36.96——¥3.749.87×
30 Jun 2024 中报¥30.70——¥3.718.27×
31 Mar 2024 一季报¥27.13——¥3.867.03×

Consensus Forward EPS 机构预测每股收益

Fiscal Year 年度EPS Median 中值Range 区间Brokers 机构数Forward P/E 预测市盈率
2026¥0.80¥0.69 to ¥0.91476.6×
2027¥0.82¥0.78 to ¥0.88474.3×
2028¥0.98¥0.93 to ¥1.13462.6×
Not Computed 未计算
  • Dividend Yield 股息率
  • Free Cash Flow 自由现金流
  • EV/EBITDA